Tiotropium
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tiotropium: From Bronchitis, Asthma and Emphysema to Obstructive Lung Disease
One-Sentence Summary
Tiotropium is a long-acting inhaled bronchodilator, originally used for airway diseases such as bronchitis, asthma and pulmonary emphysema. The TxGNN model predicts it may be effective for obstructive lung disease, but this is essentially a broader category covering the drug's existing uses (mainly COPD), so it is closer to an on-label match than true repurposing. Currently, many registered clinical trials (including multiple large Phase 3 trials) and numerous publications support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bronchitis, asthma, intrinsic asthma, allergic asthma, pulmonary emphysema (knowledge-graph indications; the approved indication text in the Singapore licences is blank) |
| Predicted New Indication | Obstructive lung disease |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, tiotropium is a long-acting muscarinic antagonist (LAMA). It blocks M3 receptors on airway smooth muscle, which reduces cholinergic bronchoconstriction and produces sustained bronchodilation.
Obstructive lung disease is the parent category of the drug's established indications (COPD, asthma, emphysema). The prediction is therefore a class-level, on-label match rather than a new therapeutic area. Many of the listed trials are COPD trials, and the trial list overlaps substantially with the separate COPD prediction.
Other lower-ranked predictions (for example respiratory malformation, Rienhoff syndrome, tracheal stenosis, interstitial emphysema) have no direct supporting evidence. Their scores most likely reflect knowledge-graph proximity rather than genuine therapeutic potential.
Clinical Trial Evidence
The most relevant trials are listed below. Many more COPD and asthma trials were identified than shown here.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00240435 | Phase 3 | Completed | 491 | Double-blind, placebo- and ipratropium-controlled 12-week comparison of tiotropium Respimat (5 and 10 mcg) in COPD, assessing bronchodilator efficacy and safety |
| NCT01431274 | Phase 3 | Completed | 2624 | 52-week TONADO 1 trial of tiotropium + olodaterol versus the individual components in COPD |
| NCT00877383 | Phase 3 | Completed | 1142 | Indacaterol added to tiotropium versus tiotropium alone over 12 weeks in moderate-to-severe COPD |
| NCT00900731 | Phase 3 | Completed | 1598 | Indacaterol versus tiotropium over 12 weeks in moderate-to-severe COPD |
| NCT01854645 | Phase 3 | Completed | 2103 | 24-week study of PT003, PT005 and PT001 versus placebo and open-label tiotropium in moderate-to-very severe COPD |
| NCT01316380 | Phase 3 | Completed | 465 | Tiotropium Respimat (2.5 and 5 µg) versus placebo over 12 weeks in mild persistent asthma on top of inhaled corticosteroids |
| NCT00772538 | Phase 3 | Completed | 459 | 48-week add-on tiotropium versus placebo in severe persistent asthma |
| NCT00157235 | Phase 3 | Completed | 234 | Effect of tiotropium on exercise tolerance during pulmonary rehabilitation in COPD |
| NCT01610037 | Phase 3 | Completed | 1215 | 52-week long-term safety of QVA149 versus placebo and tiotropium in COPD |
| NCT02172443 | Phase 3 | Completed | 50 | Tiotropium capsule versus ipratropium MDI; small active-comparator study in COPD |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28877027 | 2017 | RCT | N Engl J Med | Tested whether long-term tiotropium improves lung function and slows its decline in mild-to-moderate COPD |
| 16844726 | 2006 | Meta-analysis | Thorax | Systematic review of tiotropium efficacy on clinical events, symptoms, lung function and adverse events in stable COPD |
| 25046211 | 2014 | Systematic review | Cochrane Database Syst Rev | Updated review of tiotropium versus placebo in COPD, including soft mist inhaler trials |
| 15846642 | 2005 | Systematic review | Cochrane Database Syst Rev | Review of inhaled tiotropium in stable COPD |
| 29779416 | 2018 | RCT | Am J Respir Crit Care Med | SUNSET trial of de-escalating long-term triple therapy to indacaterol/glycopyrronium in COPD |
| 32727455 | 2020 | Review | Respir Res | Review of tiotropium's clinical development in COPD; LAMA monotherapy is recommended as initial therapy for GOLD groups B, C and D |
| 21672999 | 2011 | Meta-analysis | BMJ | Mortality risk associated with the tiotropium mist inhaler in COPD (a safety signal to be aware of) |
| 32274526 | 2020 | Meta-analysis | Eur J Clin Pharmacol | Association between tiotropium and cardiovascular events in COPD; the topic is described as controversial |
| 12010082 | 2002 | Review | Drugs | Tiotropium antagonises M1, M2 and M3 receptors and has a long duration of action permitting once-daily dosing |
| 31119643 | 2019 | Review | Drugs | Review of tiotropium/olodaterol fixed-dose combination in COPD |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15885P | SPIRIVA® RESPIMAT® Re-usable Solution for Inhalation 2.5 microgram | Solution | Not stated in the available data |
| SIN15890P | SPIOLTO® RESPIMAT® Re-usable Solution for Inhalation 2.5 microgram / 2.5 microgram | Solution | Not stated in the available data |
Safety Considerations
- Contraindications / risk conditions (from knowledge-graph associations, not label text): benign prostatic hyperplasia, impaired renal function, angle-closure (closed-angle) glaucoma, and bladder neck obstruction. These are consistent with the known anticholinergic effects of the drug class.
- Drug Interactions: The interaction screen returned 100 records. The main concerns are additive anticholinergic effects (moderate level) with other antimuscarinics such as hyoscyamine, atropine, glycopyrronium, clidinium, dicyclomine, trospium, mepenzolate, methscopolamine, propantheline and scopolamine. Other moderate interactions include eluxadoline, prucalopride and inhaled human insulin. Cimetidine is a minor interaction.
- Related study signals: One trial examined tiotropium's effect on anterior chamber and intraocular parameters (relevant to glaucoma risk). Meta-analyses have discussed possible cardiovascular and mist-inhaler mortality signals, and these remain debated.
Please also refer to the package insert for full safety information, as label warnings were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple large Phase 3 randomised trials and meta-analyses support tiotropium in obstructive lung disease, mainly COPD, and the drug is already marketed in Singapore. However, this is an on-label, class-level prediction rather than genuine repurposing. The other predicted indications have little or no evidence and should stay on Hold.
To proceed, the following is needed:
- Singapore package insert warnings, contraindications and approved indication text (the licence records have blank indication fields)
- Detailed mechanism of action data
- A screening plan for anticholinergic risks (glaucoma, urinary retention or prostatic hyperplasia, renal impairment) and for concurrent antimuscarinic use
- Clarification of which obstructive disease subtypes (for example the COPD and asthma populations) are the intended target, so that the work does not duplicate existing labelled uses
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.